FDA Approves New Treatment Option for Patients with Severe Asthma.

Updated on Friday, November 6, 2015

Atlanta Allergy & Asthma News
The U.S. Food and Drug Administration has recently approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older.

Nucala is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. If you or your child are not well controlled, we encourage you to schedule a follow up appointment to discuss this treatment option with your Atlanta Allergy & Asthma physician.